Targeting excessive cholesterol deposition alleviates secondary lymphoedema
Article Meta
Article Date: 11 February 2026
Article URL: https://www.nature.com/articles/s41586-025-10016-y
Article Title: Targeting excessive cholesterol deposition alleviates secondary lymphoedema
Article Image: (not provided)
Summary
This Nature study identifies abnormal cholesterol accumulation as a driver of secondary lymphoedema (LE) and shows that enhancing cholesterol removal can ameliorate pathological features. Using human clinical samples, several mouse models (including Apoe−/− hypercholesterolaemic mice and surgical postsurgical LE models) and lipidomics, the authors demonstrate that free and esterified cholesterol accumulates in dermal adipose tissue and around lymphatic vessels, coinciding with inflammation, adipocyte hypertrophy and fibrosis. Therapeutic interventions that promote cholesterol efflux—human HDL, apolipoprotein A‑I (ApoA‑I) and cyclodextrin—reduced tissue cholesterol, decreased inflammation and fibrosis, improved lymphatic transport and promoted lymphatic vessel regeneration in mice. The paper suggests cholesterol removal as a promising strategy to treat secondary lymphoedema and provides mechanistic and preclinical evidence to support translation.
Key Points
- Clinical lymphedema tissue shows elevated free and esterified cholesterol deposited in dermal adipose tissue and around lymphatic vessels, with associated inflammation and adipocyte enlargement.
- Apoe−/− hypercholesterolaemic mice recapitulate key human LE features: lymphatic dysfunction, adipose remodelling, macrophage infiltration and fibrosis.
- Enhancing cholesterol efflux using HDL or ApoA‑I intravenously reduces skin cholesterol, lowers inflammation and improves lymphatic tracer transport in mice.
- Cyclodextrin treatment mobilises cholesterol from tissue, reduces cholesterol around lymphatic collectors and improves outcomes in postsurgical murine lymphedema models.
- Relieving cholesterol deposits promotes lymphatic vessel regeneration and reconnection, linking lipid clearance mechanistically to functional recovery of lymphatics.
Content summary
The authors combined patient biopsies, advanced imaging, lipidomic profiling and multiple mouse models to map cholesterol distribution in lymphedematous tissue. They show cholesterol accumulates in dermal adipose tissue and forms foam‑cell like macrophage populations in advanced disease. In Apoe−/− mice maintained on a high‑fat diet, lymphatic transport is impaired and skin exhibits adipose expansion, pro‑inflammatory gene expression and fibrosis—mirroring human pathology. Short courses of HDL or ApoA‑I lowered skin cholesterol and improved lymphatic function. Cyclodextrin, a small molecule known to extract cholesterol, decreased tissue cholesterol and improved lymphatic regeneration after surgical injury. The data support a model in which failed cholesterol clearance promotes local inflammation, adipogenesis and fibrosis, which in turn worsen lymphatic insufficiency; restoring cholesterol efflux breaks this cycle.
Context and relevance
Lymphoedema affects many patients after cancer surgery or due to lymphatic injury and currently has limited pharmacological options. This study links lipid biology and lymphatic pathology, building on prior work on cholesterol transport and lymphatic function. It suggests repurposing or developing cholesterol‑mobilising therapies (for example HDL‑based approaches or cyclodextrins) as a new avenue to treat secondary lymphoedema. For researchers and clinicians, this bridges cardiovascular lipid science, immunometabolism and lymphatic biology and points to measurable biomarkers (tissue cholesterol) and actionable interventions.
Why should I read this?
Short answer: because it might actually change how we think about treating lymphedema. The paper pulls together human samples and solid preclinical work to show that fat and fibrosis in LE aren’t just passive consequences — they are driven in part by cholesterol build‑up. If you care about new, potentially druggable approaches for post‑surgical lymphoedema (or about how lipids mess with immune and vascular systems), this is worth a quick read — the interventions tested are practical and translational.
Author’s take — punchy
Punchy summary: excessive cholesterol clogs the lymphatic neighbourhood, stokes inflammation and fat growth, and blocking that clogging — with HDL, ApoA‑I or cyclodextrin — helps the lymphatics heal. High translational potential; watch this space.